The US Food and Drug Administration (FDA) has approved Dermira Inc.’s Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of excessive armpit sweating, or primary axillary hyperhidrosis, in adult and pediatric patients aged ≥9 years. About 10 million people are affected with the condition, which results in sweating beyond what is needed for regulating normal body temperature, and can affect a person’s psychological well-being and overall quality of life. Dermira Inc. is headquartered in Menlo Park, CA.
Administration: Patients should use 1 cloth to apply Qbrexza to both axillae by wiping the cloth across 1 underarm, one time. Using the same cloth, apply the medication to the other underarm, one time. Qbrexza can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes. Patients should be instructed to wash their hands with soap and water immediately after discarding the used cloth.
Adverse reactions: Most common adverse reactions (incidence ≥2%) are dry mouth, mydriasis, oropharyngeal pain, headache, urinary hesitation, vision blurred, nasal dryness, dry throat, dry eye, dry skin, and constipation. Local skin reactions, including erythema, burning/stinging, and pruritus were also common (>5%).
Dermira receives FDA approval for Qbrexza (glycopyrronium) cloth to treat primary axillary hyperhidrosis. [news release]. Menlo Park, CA: Dermira Inc. June 29, 2018. http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2356602. Accessed July 6, 2018.
This Week's Must Reads
Actinic Keratosis Treatment Burden in Medicare , JAMA Dermatology; ePub 2018 Sep 19; Yeung, et al
Surgical Fire Risk in Mohs Surgery is Minimal, Dermatolog Surg; ePub 2018 Sep 17; Li, et al
Dermatologic Procedures Independently Billed by NPPs, J Am Acad Dermatol; ePub 2018 Sep 15; Qi, Hibler, et al
Incidence of Oral SCC Risk in Oral Lichen Planus, Int J Dermatol; ePub 2018 Sep 14; Lanoisz, et al
Sentinel Lymph Node Positivity Markers in Melanoma, J Am Acad Dermatol; ePub 2018 Sep 18; Conic, et al
Must Reads in FDA Actions
FDA Approves Qbrexza for Excessive Armpit Sweating, Dermira Inc. news release; 2018 Jun 29
FDA Approves Drug Combination for Melanoma, Array BioPharma news release; 2018 Jun 27
FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7
FDA Extends Label for Cimzia for Plaque Psoriasis, UCB news release; 2018 May 29
FDA Updates Label for Taltz for Genital Psoriasis, PharmaLive news release; 2018 May 22